Diabetes

The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.

Latest News

Rural health sign | Image credit: BJP7images - stock.adobe.com
FQHCs Show Low Engagement in Hypertension, Diabetes Trials

April 15th 2025

A new review finds federally qualified health centers (FQHCs) are underutilized in hypertension and type 2 diabetes clinical research, despite their potential to improve trial diversity.

AI representation of housing stability | Image credit: GoldPumaze - stock.adobe.com
Housing Instability Linked to Worse Type 2 Diabetes Outcomes

April 14th 2025

Diabetes concept | Image credit: Sherry Young - stock.adobe.com
GLP-1 RAs, SGLT2 Inhibitors Associated With Reduced MACE, HHF in Patients With Diabetes

April 9th 2025

AJMC
The Role of Advanced Technologies in Improving Diabetes Outcomes

April 7th 2025

Diabetes - Vitalii Vodolazskyi - stock.adobe.com.jpg
More Than 250 Million Individuals Unaware They Have Diabetes

April 7th 2025

More News

technology graphic
December 6th 2021

Review: Smartphone Apps May Improve Outcomes in Gestational Diabetes

Gianna Melillo
Results of a systemic review found evidence potentially supporting the use of smart phone applications among mothers with gestational diabetes.
diabetes graphic
December 1st 2021

Does Gender-Affirming Hormone Therapy Affect T2D Risk?

Gianna Melillo
Results of a cohort study showed that transfeminine individuals may be at a higher risk for type 2 diabetes (T2D) compared with cisgender females, but revealed little evidence that gender-affirming hormone therapy impacts diabetes risk.
pill graphic
November 29th 2021

Variability in Statin Use Seen Among Finnish T2D Population

Gianna Melillo
Data showed differences in statin use to prevent cardiovascular disease among Finnish patients with type 2 diabetes.
Jordan Messler, MD, SFHM,
November 22nd 2021

Contributor: CMS Has Decided to Put Its Muscle Behind Glycemic Management—Why Now?

Jordan Messler, MD, SFHM, FACP
CMS' introduction of 3 new electronic clinical quality measures, 2 of which are focused on inpatient glycemic management, signal a strong commitment to shine a light on this often-overlooked area, according to the chief medical officer at Glytec.
Robert A. Gabbay, MD, PhD
November 16th 2021

Dr Robert Gabbay Outlines How the Health Equity Now Initiative Addresses Diabetes Care Disparities

Hayden E. Klein
Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, explains the Health Equity Now initiative and how it shines a light on health disparities.
Robert A. Gabbay, MD, PhD
November 10th 2021

Dr Robert Gabbay on COVID-19 Vaccinations in the Diabetes Community

Hayden E. Klein
Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses COVID-19 vaccinations among people with diabetes as they have been disproportionally affected by the pandemic.
Site Logo
November 10th 2021

Challenges With Implementing the Diabetes Prevention Program for Medicare Beneficiaries in an Integrated Health System

Inga Gruß, PhD Alison Firemark, MA Dea Papajorgji-Taylor, MPH Stephanie L. Fitzpatrick, PhD
This study presents challenges of implementing the CDC-approved Diabetes Prevention Program for Medicare beneficiaries at a large, integrated health care delivery system.
woman at doctor's
November 8th 2021

Analysis Details Factors Associated With T2D Development Among Women With PCOS

Gianna Melillo
Results of a cross-sectional study detail characteristics among women with polycystic ovary syndrome (PCOS) who develop type 2 diabetes.
america graphic
November 3rd 2021

Study Evaluates Impact of Food Environments on T2D Risk

Gianna Melillo
Results of a longitudinal study indicate community food accessibility factors may impact type 2 diabetes risk among veterans.
inclusivity image
October 31st 2021

Research Highlights Racial/Ethnic Diabetes Disparities Based on Age of Diagnosis

Gianna Melillo
New research underscores racial/ethnic diabetes disparities in the United States.
Robert Gabbay, MD, PhD
October 29th 2021

Dr Robert Gabbay Discusses SGLT2 Inhibitor Uptake Among Cardiologists, Nephrologists

Hayden E. Klein
As time goes on, we're finding out more and more benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association.
old man
October 26th 2021

Intensifying Diabetes Medication Regimen at Hospital Discharge May Not Benefit Older Patients

Gianna Melillo
Results of a retrospective study found no benefits among older patients whose diabetes medication was intensified following short hospital admissions.
Site Logo
October 20th 2021

Hypoglycemia Upon Hospital Admission From Long-term Care: Health Care Resource Use

Naushira Pandya, MD, CMD Alyssa Trenery, PharmD, MPH Ray Sieradzan, PharmD Claudia Gabai, MPH Anastasia Ermakova, PharmD Yan Xiong, MS
This analysis of a hospital billing database describes inpatient length of stay, intensive care unit length of stay, comorbidities, and costs for patients with diabetes after admission with hypoglycemia from long-term care or home.
diabetes graphic
October 18th 2021

Insulin Analogs, Pen Delivery Devices Most Used Among Patients With T2D

Gianna Melillo
Using data from a nationally representative sample, investigators sought to determine trends in insulin device use.
Light Drinking Linked With Lower Risk of Type 2 Diabetes for Some Women
October 15th 2021

Light Drinking Linked With Lower Risk of Type 2 Diabetes for Some Women

Hayden E. Klein
Some alcohol, but not more than 1 drink per day, was linked to a 55% lower risk of type 2 diabetes in women with a history of gestational diabetes.
diabetes graphic
October 11th 2021

Study Finds Statin Use Associated With Diabetes Progression

Gianna Melillo
Using electronic medical record data from Veterans Affairs, researchers found statin use was associated with a greater risk of diabetes progression.
Site Logo
October 8th 2021

Patient and Supporter Factors Affecting Engagement With Diabetes Telehealth

Margaret F. Zupa, MD John D. Piette, PhD Shelley C. Stoll, MPH D. Scott Obrosky, MS Monique Boudreaux-Kelly, PhD Ada O. Youk, PhD Luc Overholt, MD Ranak Trivedi, PhD Michele Heisler, MD, MPH Ann-Marie Rosland, MD, MS
Family support with medication management and recent urgent self-management concerns are 2 novel factors, among others, that predict completion of diabetes telehealth calls.
Diabetic Nephropathy, Obesity Increase COVID-19 Mortality Risk in Patients With Type 2 Diabetes
October 4th 2021

Diabetic Nephropathy, Obesity Increase COVID-19 Mortality Risk in Patients With Type 2 Diabetes

Hayden E. Klein
Patients with T2D had elevated blood glucose levels but there were no notable differences in levels between surviving and non-surviving patients with T2D.
Deepak Bhatt, MD, MPH
September 29th 2021

Dr Deepak Bhatt on the Importance of In-Hospital Initiation of SGLT2 Inhibitors

Gianna Melillo
Deepak L. Bhatt, MD, MPH, outlines the benefits of starting patients on sodium glucose co-transporter 2 (SGLT2) inhibitors while they are hospitalized.
doctor writing script
September 27th 2021

Medicaid Expansion Linked With Reduction in Uninsurance and Improved Blood Pressure, Glucose Control Measures

Gianna Melillo
Results of a representative study of patients at federally qualified health centers found Medicaid expansion was associated with reduced rates of uninsurance, improved blood pressure and diabetes control measures, and progress in closing racial care disparities over 5 years.
David G. Armstrong
September 21st 2021

Managing the Surge: Delayed Chronic Wound Care During COVID-19

David G. Armstrong, DPM, MD, PhD
Encourage Further SGLT2 Inhibitor Treatment for Diabetes, Kidney Disease, Expert Says
September 20th 2021

Encourage Further SGLT2 Inhibitor Treatment for Diabetes, Kidney Disease, Expert Says

Hayden E. Klein
New data from the CREDENCE trial shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce hyperkalemia risk in people with type 2 diabetes and chronic kidney disease who are using RAAS inhibitors.
sugar rising
September 10th 2021

Presentation Outlines Long-term CV Risks of Gestational Diabetes

Gianna Melillo
A session at the 5th annual Heart in Diabetes Conference highlights the long-term risks of gestational diabetes.
covid 19 graphic
September 10th 2021

Research Highlights Benefits of Aspirin, Monoclonal Antibody Use in Patients With Diabetes, COVID-19

Gianna Melillo
New research presented at the 5th Heart in Diabetes Conference highlights potential therapeutic options for patients with COVID-19 and diabetes.
FDA Grants Empagliflozin Breakthrough Therapy Designation in HFpEF
September 9th 2021

FDA Grants Empagliflozin Breakthrough Therapy Designation in HFpEF

Mary Caffrey
The sodium glucose co-transporter 2 (SGLT2) inhibitor reduced cardiovascular death and hospitalization for heart failure by 21% in results presented August 27 during the recent European Society of Cardiology Congress.
David McIntyre, MD, FRACP
September 7th 2021

Dr David McIntyre on Care Takeaways From COVID-19 for Pregnant Patients With Diabetes

Gianna Melillo
David McIntyre, MD, FRACP, describes lessons learned from the pandemic for ensuring appropriate continuation of care for pregnant patients with diabetes.
Increase in Both Type 1 and Type 2 Diabetes Seen Among US Youth Over 16-Year Period
September 2nd 2021

Increase in Both Type 1 and Type 2 Diabetes Seen Among US Youth Over 16-Year Period

Hayden E. Klein
Native American and Black youth aged 10 to 19 years had the highest incidence of type 2 diabetes overall.
Deepak Bhatt, MD, MPH
August 30th 2021

Dr Deepak L. Bhatt Discusses SGLT Inhibitors’ Impact on Glycemic Control

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the role that sodium glucose co-transporter (SGLT) inhibitors play in patients with diabetes and diminished glomerular filtration rates.
scale and tape measure
August 26th 2021

USPSTF Lowers Recommended T2D, Prediabetes Screening Age to 35 Years

Gianna Melillo
The United States Preventive Services Task Force (USPSTF) lowered its recommended screening age for type 2 diabetes and prediabetes from 40 to 35 years among overweight and obese individuals.
Site Logo
August 25th 2021

Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 Diabetes

Manjiri Pawaskar, PhD S. Pinar Bilir, MS Stacey Kowal, MS Qianyi Li, MS Tracey Weiss, MPH Glenn Davies, DrPH
Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.
<1
...
67891011121314
...
98>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo